Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search
- PMID: 29232548
- DOI: 10.1016/j.ccell.2017.11.013
Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search
Abstract
In this issue of Cancer Cell, Gong et al. have analyzed the sensitivity of 560 cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined cancers with specific genomic "D-cyclin activating features (DCAF)" as particularly vulnerable. These findings will facilitate patient selection as development of this drug class continues.
Copyright © 2017 Elsevier Inc. All rights reserved.
Comment on
-
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.Cancer Cell. 2017 Dec 11;32(6):761-776.e6. doi: 10.1016/j.ccell.2017.11.006. Cancer Cell. 2017. PMID: 29232554
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
